Posted by Michael Wonder on 04 May 2025
Health Canada accepts semaglutide 2.4 mg, a GLP-1 receptor agonist treatment for MASH, as a supplemental new drug submission under the priority review policy
2 May 2025 - Today, Novo Nordisk Canada announced that Health Canada has accepted for review, under the priority review policy, its supplemental new drug submission for semaglutide 2.4 mg, a once weekly therapy for people living with MASH (metabolic dysfunction-associated steatohepatitis).
Semaglutide injection 2.4 mg is currently approved by Health Canada for chronic weight management and non-fatal myocardial infarction risk reduction in adults with established cardiovascular disease and BMI ≥ 27 kg/m2.
